IRCT20260806070555N1 IRCT 2026-08-18 Lady Reading Hospital /MTI oral melatonin in Melasma efficacy of oral melatonin in melasma Efficacy of oral melatonin vs oral tranexemic acid in the treatment of melasma 2026-09-01 anticipated 180 Recruiting https://irct.ir/trial/92376 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants will be recruited through non-probability consecutive sampling. After enrollment, participants will be randomly allocated in a 1:1 ratio to either the oral melatonin group or the oral tranexamic acid group using a simple lottery method. Sequentially numbered opaque sealed envelopes containing group assignments will be prepared before recruitment. Each participant will draw one envelope, and the assignment inside will determine the treatment group. Randomization will be performed at the individual participant level. Allocation concealment will be maintained until the envelope is opened at the time of assignment. N/A Epidermal Melasma : Its characterized by hyperpigmented macules and patches on face due to excess melanin accumulation in the skin. It can be confirmed by woods lamp examination where the pigmentation becomes accentuated.. Intervention 1: Intervention group: Participants will receive oral melatonin 3 mg once daily at bedtime for 12 weeks, along with standard sun protection measures and broad-spectrum sunscreen. Intervention 2: Control group: Participants will receive oral tranexamic acid 250 mg twice daily for 12 weeks, along with standard sun protection measures and broad-spectrum sunscreen. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information